<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Human and <z:mp ids='MP_0001799'>viral</z:mp> interleukin-10 (IL-10) possess growth factor activity for human B cells and may act as autocrine growth factors in B cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>To study this possibility we have measured <z:mp ids='MP_0001799'>viral</z:mp> (v) and human (h) IL-10 expression in EBV-positive and negative B lineage <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell lines </plain></SENT>
<SENT sid="2" pm="."><plain>Previous studies demonstrated IL-10 expression in cell lines and now we describe the pattern of IL-10 expression in primary Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> biopsies and in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> lines of defined phenotypes </plain></SENT>
<SENT sid="3" pm="."><plain>vIL-10 was expressed during the lytic (productive) phase of <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e>, but not during virus latency </plain></SENT>
<SENT sid="4" pm="."><plain>Although hIL-10 was expressed in the majority of B cell lines, it was not expressed in two <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> biopsy specimens </plain></SENT>
<SENT sid="5" pm="."><plain>Expression of hIL-10 did not correlate with the presence of EBV, but was associated with the differentiation state of the B cell line </plain></SENT>
<SENT sid="6" pm="."><plain>Thus, vIL-10 may enhance the persistence of B cells infected at sites of virus replication, and while hIL-10 may be a factor in the growth both in vivo and in vitro of some <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLs</z:e> and EBV-transformed B cells, it is not an absolute requirement </plain></SENT>
</text></document>